MedTrace Logo

A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)

NCT00679055 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-08-17

Study results available
· View outcomes & findings →

Summary

A 12-Week Efficacy Study in participants with Peripheral Arterial Disease. the primary hypothesis is that MK-0736 7 mg administered once daily for 12 weeks will result in a decrease in lower extremity atherosclerotic plaque macrophage content when compared to placebo (an approximate decrease of up to 30% is expected).

Conditions

  • Peripheral Vascular Diseases

Interventions

DRUG

MK-0736

MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.

DRUG

Comparator: placebo (unspecified)

Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-08-26
Completion
2008-08-26

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00679055 on ClinicalTrials.gov